Iindaba

Kwimeko yeklinikhi evunyiweyo, isigulane esineminyaka engama-21 ubudala soyise ngempumelelo imingeni ye-thalassemia ngokusebenzisa unyango lwe-gene olusekelwe kwi-CRISPR. Le ndlela intsha iphawula inqanaba elibalulekileyo kunyango lweengxaki zegazi ezinzima ezifana nesifo se-sickle cell (SCD) kunye ne-thalassemia.

Kwingqungquthela ezayo ye-ASH 2024, iqela lezonyango leSibhedlele iLu Daopei liza kubonisa iziphumo zophando ezili-13 ezibalaseleyo, ligxininisa inkqubela phambili kwi-hematology kunye namathuba onyango lwe-CAR-T, liqinisekisa kwakhona ukuzibophelela kwabo ekuphuculeni iziphumo zesigulana.

Emva kokulwa ne-lymphoma iminyaka emithathu, umfazi oneminyaka engama-61 ubudala ufumene ukuphumla ngokupheleleyo ngonyango olutsha lwe-CAR-T oluphindwe kabini kwi-BIOOCUS, ebonisa amandla okutshintsha ubomi bonyango lomhlaza oluphambili.

Uphuhliso lwakutshanje kwiteknoloji yeCRISPR/Cas lutshintsha indlela ehlelwe ngayo i-gene kuphando lwezonyango. Eli nqaku liphonononga ukusetyenziswa kwayo, ligxininisa amandla abalulekileyo okunyanga iingxaki ze-genetic, umhlaza, kunye nezifo ezosulelayo.

Ityala elimangalisayo kwi-BIOOCUS libonisa impembelelo yotshintsho yonyango lwe-CD7 CAR-T kwinkwenkwe eneminyaka eli-15 ubudala ene-T-cell acute lymphoblastic leukemia (T-ALL) ephinde yabuyela kwisifo, nto leyo ekhokelela ekuxolelweni ngokupheleleyo kunye nokufakelwa kwesibini okuphumelelayo.

I-Bioocus inomdla wokujoyina iNgqungquthela yesi-8 ye-Immuno-Gene kunye neCell Therapy (IGC 2024)! Silangazelela ukusebenzisana neengcali zehlabathi kunye nokuhlola iimodeli ezintsha zoshishino ezihambelana nobuchwepheshe be-gene kunye ne-cell therapy obuphambili. Sisonke, masiyile ikamva le-immunotherapy.

Eli nqaku leendaba ligxininisa uphando lwakutshanje malunga nokulawula ubuthi be-CAR-T cell therapy kwi-B-cell lymphomas. Olu phononongo lugxininisa amaqhinga okujongana neziphumo ebezingalindelekanga ezifana ne-cytokine release syndrome (CRS) kunye ne-neurotoxicity (ICANS), ukuqinisekisa ukusetyenziswa okukhuselekileyo kolu nyango luphambili.

Uphando lwamva nje lubonisa ukusebenza kakuhle kunye nokhuseleko lwe-CD7 CAR-T cell therapy ekunyangeni i-B-cell acute lymphoblastic leukemia (B-ALL) ephinde yabuyela kwi-relaxation okanye i-refractory kunye ne-T-cell lymphoblastic lymphoma (T-LBL). Olu phando luqhutywa yi-BIOOCUS ngokubambisana neSibhedlele iLu Daopei, lubonisa iziphumo ezithembisayo kwizigulana, zibonelela ngenye indlela enamandla endaweni ye-chemotherapy eqhelekileyo.

Olu phononongo, olupapashwe kwi- Ijenali ye-Clinical Oncology, ibonisa amazinga aphezulu okuxolelwa kwizigulane ezazisele zisebenzise iindlela zonyango zemveli, nto leyo ebonisa inkqubela ethembisayo kunyango lomhlaza.

Uphononongo lwakutshanje lubonisa ukusebenza kakuhle konyango lwe-CD7 CAR-T olulandelwa lutyando lwesibini lwe-allogeneic hematopoietic stem cell transplantation (HSCT) kwizigulane ezine-T-cell acute lymphoblastic leukemia (T-ALL) ephinde yafunyanwa kunye ne-lymphoblastic lymphoma (LBL), nto leyo ebonisa amandla amakhulu ekufezekiseni ukukhululwa okupheleleyo kwe-minimal residual disease (MRD)-negative.

Uphononongo oluphambili lubonisa impumelelo yexesha elide yonyango lwe-CD19 CAR T-cell ekunyangeni izigulana ezine-relapse/refractory acute lymphoblastic leukemia (ALL) emva kokufakelwa kweeseli ze-hematopoietic stem, nto leyo enika ithemba elitsha kwi-hematology.

I-Bioocus iphambili ekuphuhliseni unyango lwe-CAR-T lwesizukulwana esilandelayo. Impapasho yakutshanje kaGqr. Chunrong Tong kunye neqela lakhe kwiSibhedlele saseLu Daopei igxininisa inkqubela phambili ebalulekileyo kunye nemingeni ekusetyenzisweni konyango lwe-CD19 CAR-T lwesizukulwana sesibini kwizigulana zabantwana, ibonisa ukuzinikela kweBioocus kunyango lomhlaza olutsha.